Sudocetaxel Zendusortide
- Generic Name
- Sudocetaxel Zendusortide
TH1902 in Patients With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid TumorHormone Receptor-positive Breast CancerCutaneous MelanomaSmall-cell Lung CancerEndometrial CancerSORT1+ CancersTNBC - Triple-Negative Breast CancerEpithelial Ovarian CancerProstate CancerThyroid Cancer
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Theratechnologies
- Target Recruit Count
- 70
- Registration Number
- NCT04706962
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
🇺🇸Pennsylvania Cancer Specialists Research Institute, Gettysburg, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath